Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Harpoon Therapeutics Inc (HARP)
Harpoon Therapeutics Inc (HARP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 24,830
  • Shares Outstanding, K 33,107
  • Annual Sales, $ 23,650 K
  • Annual Income, $ -116,720 K
  • 60-Month Beta 1.57
  • Price/Sales 0.77
  • Price/Cash Flow N/A
  • Price/Book 1.47
Trade HARP with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.16
  • Most Recent Earnings -0.35 on 11/14/22
  • Next Earnings Date 03/23/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 466.90% ( +72.43%)
  • Historical Volatility 132.35%
  • IV Percentile 87%
  • IV Rank 29.49%
  • IV High 1,490.52% on 11/15/22
  • IV Low 38.78% on 08/11/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 50
  • Volume Avg (30-Day) 164
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 4,548
  • Open Int (30-Day) 3,884

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.29
  • Number of Estimates 1
  • High Estimate -0.29
  • Low Estimate -0.29
  • Prior Year -0.66
  • Growth Rate Est. (year over year) +56.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6100 +20.08%
on 03/14/23
0.8709 -15.89%
on 02/22/23
-0.1196 (-14.04%)
since 02/17/23
3-Month
0.5857 +25.06%
on 12/29/22
1.4500 -49.48%
on 02/07/23
+0.0677 (+10.18%)
since 12/20/22
52-Week
0.5857 +25.06%
on 12/29/22
5.1600 -85.80%
on 04/01/22
-3.9475 (-84.35%)
since 03/18/22

Most Recent Stories

More News
Ardelyx (ARDX) Surpasses Q4 Earnings and Revenue Estimates

Ardelyx (ARDX) delivered earnings and revenue surprises of 500% and 59.45%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ARDX : 3.90 (-3.70%)
HARP : 0.7325 (-2.33%)
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of 10.87% and 246.74%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ACRS : 8.16 (+3.42%)
HARP : 0.7325 (-2.33%)
New Strong Buy Stocks for January 27th

GWRS, EVBG, SPLK, RELL and HARP have been added to the Zacks Rank #1 (Strong Buy) List on January 27, 2023.

RELL : 20.85 (+3.47%)
SPLK : 90.21 (+1.19%)
GWRS : 12.81 (+0.71%)
EVBG : 32.60 (-1.39%)
HARP : 0.7325 (-2.33%)
Why Fast-paced Mover Harpoon Therapeutics, Inc. (HARP) Is a Great Choice for Value Investors

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Harpoon Therapeutics, Inc. (HARP) could be a great choice. It is one of the several stocks...

HARP : 0.7325 (-2.33%)
MarketBeat: Week in Review 12/12 - 12/16

A triple-witching day means it could be a rough end to a trading week. Before you step away for the holidays, here are some of the top articles from this week.

BILI : 23.94 (+7.94%)
PLAY : 36.11 (+5.31%)
MULN : 0.1266 (-9.57%)
NVDA : 257.30 (+0.02%)
AMD : 95.00 (-2.90%)
LULU : 296.06 (+0.45%)
TSCO : 234.10 (+0.71%)
HARP : 0.7325 (-2.33%)
KSS : 23.55 (+1.38%)
Harpoon Therapeutics Remains Volatile After Promising News

Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%.

HARP : 0.7325 (-2.33%)
AMGN : 232.28 (+1.08%)
GILD : 78.71 (+1.81%)
REGN : 750.76 (+0.42%)
VRTX : 298.41 (+0.89%)
MRNA : 154.89 (+3.25%)
ABBV : 155.24 (+0.66%)
Three Small-Cap Biotech Stocks to Consider Now

This article looks at three small-cap biotech companies with stock prices that are making significant moves and have a bright outlook for 2023 

HARP : 0.7325 (-2.33%)
HTGM : 2.90 (+2.84%)
ABEO : 2.30 (-3.77%)
Harpoon Therapeutics (NASDAQ: HARP) Releases Updated Phase 1 Interim Results for HPN217 in Treating Relapsed Multiple Myeloma

Harpoon Therapeutics, Inc. (NASDAQ: HARP) is engaged as a clinical-stage immune-oncology company, which is focused on the research and development

HARP : 0.7325 (-2.33%)
Pre-Market Brief: Stocks Mixed As Investors Await Inflation Data, Fed meeting

December S&P 500 futures (ESZ22) are trending up +0.26% this morning after three major US benchmark indices closed lower on Friday, notching their biggest weekly drop in more than a month, as hotter-than-anticipated...

ESZ22 : 3,871.47s (-0.66%)
HARP : 0.7325 (-2.33%)
HZNP : 109.00 (-0.06%)
AMGN : 232.28 (+1.08%)
GPC : 165.22 (+1.94%)
RH : 250.38 (+1.61%)
ULTA : 506.66 (+0.04%)
LI : 23.14 (+2.43%)
Will Pacira's (PCRX) Exparel Aid Growth Amid High Reliance?

Pacira's (PCRX) flagship product Exparel, along with other marketed products, is driving year over year growth. Pacira's efforts to expand Exparel label also holds promise.

UTHR : 222.65 (+1.33%)
PCRX : 39.77 (+0.71%)
KALV : 6.98 (-5.55%)
HARP : 0.7325 (-2.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Harpoon Therapeutics Inc. is a clinical-stage immunotherapy company developing a novel class of T cell engagers which harness the power of the body's immune system to treat patients suffering from cancer and other diseases. Using its proprietary Tri-specific T cell Activating Construct(TM) platform,...

See More

Key Turning Points

3rd Resistance Point 0.8997
2nd Resistance Point 0.8499
1st Resistance Point 0.7999
Last Price 0.7325
1st Support Level 0.7001
2nd Support Level 0.6503
3rd Support Level 0.6003

See More

52-Week High 5.1600
Fibonacci 61.8% 3.4126
Fibonacci 50% 2.8728
Fibonacci 38.2% 2.3331
Last Price 0.7325
52-Week Low 0.5857

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar